Oncopeptides AB: Oncopeptides rescinds voluntary withdrawal of Pepaxto in the US - no intent to market in the US at this time

STOCKHOLM, Jan. 21, 2022 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological

Related Keywords

Sweden ,Stockholm ,United Kingdom ,Rolf Gulliksen ,Klaas Bakker ,Linda Holmstr ,Jakob Lindberg ,Drug Administration ,Global Head Of Corporate Communications ,Nasdaq Stockholm ,Overall Survival ,Global Head ,Corporate Communications ,Investor Relations ,Corporate Headquarters ,Mid Cap ,Oncopeptides ,Rescinds ,Oluntary ,Withdrawal ,Pepaxto ,Intent ,Market ,Dime ,